CompletedPhase 4ACTRN12606000457549

A randomised, double blind, placebo controlled, parallel trial of folic acid and the improvement of endothelial dysfunction in obese children and adolescents

Effects of folic acid on endothelial function in obese children and adolescents


Sponsor

Children, Youth and Women's Health Service

Enrollment

60 participants

Start Date

Jan 2, 2004

Study Type

Interventional

Conditions

Summary

Worldwide obesity has increased over the last decade. Paediatric obesity is known to be an independent risk factor for adult obesity. Adolescent obesity is associated with atherosclerosis. Atherosclerosis is preceded by endothelial or blood vessel dysfunction that can be assessed by ultrasound. Endothelial dysfunction occurs in severely obese children. Early interventions to improve endothelial dysfunction in obesity, in addition to metabolic and weight control may potentially prevent atherosclerosis and heart disease. Folic acid has been proposed as one of the strategies to reduce atherosclerosis and hasn't been investigated in obesity.


Eligibility

Sex: Both males and femalesMin Age: 10 YearssMax Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study is looking at: A randomised, double blind, placebo controlled, parallel trial of folic acid and the improvement of endothelial dysfunction in obese children and adolescents. It is open to Both males and females, aged 10 to 18. There are also some health conditions and factors that may prevent you from joining.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

5 mg oral folic acid taken daily for 8 weeks

5 mg oral folic acid taken daily for 8 weeks


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12606000457549